<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00711841</url>
  </required_header>
  <id_info>
    <org_study_id>IMIFernando Figueira</org_study_id>
    <nct_id>NCT00711841</nct_id>
  </id_info>
  <brief_title>Effectivity of Postpartum Dexamethasone for Women With Class I HELLP Syndrome</brief_title>
  <acronym>COHELLP</acronym>
  <official_title>Postpartum Dexamethasone for Women With Class I HELLP Syndrome: a Double-blind, Placebo-controled, Randomized Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Instituto Materno Infantil Prof. Fernando Figueira</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Instituto Materno Infantil Prof. Fernando Figueira</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Corticotherapy accelerates maternal postpartum recovery in women with class I HELLP syndrome.
      The benefit of faster and better recovery would be observed in fewer complications, less
      utilization of blood products and shorter hospital stay.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients with Class I HELLP Syndrome will be recruited for use os dexamethasone or placebo in
      the puerperium. Effects such as clinical course (blood pressure and diureses), laboratorial
      behaviour and complications will be compared. Duration of hospitalization will also be
      accessed.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>July 2011</start_date>
  <completion_date type="Anticipated">July 2018</completion_date>
  <primary_completion_date type="Anticipated">June 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>severe maternal morbidity</measure>
    <time_frame>postpartum</time_frame>
    <description>42 days after delivery</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>hospital stay duration</measure>
    <time_frame>postpartum</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">400</enrollment>
  <condition>HELLP Syndrome</condition>
  <arm_group>
    <arm_group_label>saline solution</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo (saline solution), 2 mL, intravenous, every 12 hours, for 48 hours</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dexamethasone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Dexamethasone, 10mg (2mL), intravenous, every 12 hours, for 48 hours</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>dexamethasone</intervention_name>
    <description>Dexamethasone, 10mg (2mL), intravenous, every 12 hours, for 48 hours</description>
    <arm_group_label>saline solution</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Saline solution, 2 mL, intravenous, every 12 hours, for 48 hours</description>
    <arm_group_label>saline solution</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>dexamethasone</intervention_name>
    <description>dexamethasone, 10mg, 2 mL, intravenous solution, every 12 hours , for 48 hours</description>
    <arm_group_label>Dexamethasone</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Postpartum women with Class I HELLP syndrome

        Exclusion Criteria:

          -  Chronic users of corticosteroids

          -  Patients with chronic conditions affecting the laboratory parameters involved in the
             HELLP syndrome

          -  Women who had received antenatal corticosteroids to treat HELLP syndrome were excluded
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>13 Years</minimum_age>
    <maximum_age>49 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Leila Katz, pHD</last_name>
    <role>Principal Investigator</role>
    <affiliation>IMIP</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Instituto Materno Infantil Prof. Fernando Figueira</name>
      <address>
        <city>Recife</city>
        <state>Pernambuco</state>
        <zip>50.070-550</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 7, 2008</study_first_submitted>
  <study_first_submitted_qc>July 7, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 9, 2008</study_first_posted>
  <last_update_submitted>March 5, 2018</last_update_submitted>
  <last_update_submitted_qc>March 5, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 6, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Instituto Materno Infantil Prof. Fernando Figueira</investigator_affiliation>
    <investigator_full_name>Leila Katz</investigator_full_name>
    <investigator_title>Obstetrical ICU obstetrical coordinator; MD , PhD</investigator_title>
  </responsible_party>
  <keyword>HELLP syndrome</keyword>
  <keyword>dexamethasone</keyword>
  <keyword>postpartum period</keyword>
  <keyword>class I HELLP syndrome</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>HELLP Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pharmaceutical Solutions</mesh_term>
    <mesh_term>Dexamethasone acetate</mesh_term>
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>BB 1101</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

